| Long-term treatment of acromegaly with octreotide (Sandostatin). | |
| | |
MedLine Citation:
|
PMID: 2192978 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sixteen patients with acromegaly have been treated with octreotide [100 micrograms twice daily to 200 micrograms 3 times daily according to growth hormone (GH) response] for between 3 and 44 months. The mean serum GH concentrations fell from 39.3 mU/l before treatment to 10.5 mU/l on day 1 of treatment and, with continued treatment (and higher doses in 8 of 16 patients), to 7.9 mU/l. In 2 patients there was no GH suppression. GH suppression after the first administration of octreotide appeared to predict long-term response. Pre-treatment serum insulin-like growth factor 1 levels were elevated in 11 of 12 patients investigated, but were normalized on continued octreotide therapy in 10 of 12. Octreotide suppressed prolactin secretion in all 6 hyperprolactinaemic patients. Steatorrhoea occurred in 15 of 16 patients at initiation of treatment, but resolved in all within 7 days. Two patients developed gallstones. In summary, octreotide is a safe and effective treatment for acromegaly, producing clinical and biochemical improvement in up to 90% of patients. Octreotide is a valuable adjunctive treatment where surgery has failed and also in those with contra-indications to surgery. |
| | |
Authors:
|
M D Page; M E Millward; M Hourihan; R Hall; N F Scanlon |
Related Documents
:
|
6539698 - Human tumour ph changes following hyperthermia and radiation therapy. 19773368 - Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours ... 2656468 - Experience of a six-month treatment with sandostatin at increasing doses in acromegaly. 16868138 - Baseline characteristics and response to gh replacement of hypopituitary patients previ... 6354498 - Effectiveness of leishmanization in the control of cutaneous leishmaniasis. 19934708 - The gross motor function classification system for cerebral palsy and single-event mult... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Hormone research Volume: 33 Suppl 1 ISSN: 0301-0163 ISO Abbreviation: Horm. Res. Publication Date: 1990 |
Date Detail:
|
Created Date: 1990-07-27 Completed Date: 1990-07-27 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0366126 Medline TA: Horm Res Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 20-30; discussion 30-1 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Wales College of Medicine, Cardiff, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acromegaly
/
drug therapy* Adult Aged Blood Glucose Female Growth Hormone / blood Humans Insulin / blood Insulin-Like Growth Factor I / analysis Male Middle Aged Octreotide / adverse effects, therapeutic use* Pituitary Neoplasms / complications Prolactin / blood Thyroid Gland / drug effects Thyrotropin / biosynthesis Thyroxine / biosynthesis |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 11061-68-0/Insulin; 67763-96-6/Insulin-Like Growth Factor I; 7488-70-2/Thyroxine; 83150-76-9/Octreotide; 9002-62-4/Prolactin; 9002-71-5/Thyrotropin; 9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lectin-binding sites in the retina of the pig, baboon and cat.
Next Document: Application of the polymerase chain reaction to the diagnosis of human genetic disease.